Plus Therapeutics Inc (PSTV)

NASDAQ
1.970
+0.090(+4.79%)
After Hours
1.970
0.000(0.00%)
- Real-time Data
  • Volume:
    1,241,332
  • Bid/Ask:
    1.900/1.970
  • Day's Range:
    1.810 - 1.970
  • Type:Equity
  • Market:United States
  • ISIN:US72941H4002
  • CUSIP:00072941H400

PSTV Overview

Prev. Close
1.88
Day's Range
1.81-1.97
Revenue
-
Open
1.85
52 wk Range
1.75-5.42
EPS
-1.64
Volume
1,241,332
Market Cap
30.16M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,352,753
P/E Ratio
-
Beta
0.36
1-Year Change
-32.99%
Shares Outstanding
15,310,025
Next Earnings Date
Nov 11, 2021
What is your sentiment on Plus Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Plus Therapeutics Inc News

Plus Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyNeutralStrong Sell
Technical IndicatorsBuyStrong BuyStrong BuySellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Sell

Plus Therapeutics Inc Company Profile

Plus Therapeutics Inc Company Profile

Employees
12

Plus Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The Company also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.

Read More
  • Zero sales but everyone says strong buy - always confused with this Co but stuck n feels like slow quiksand
    0
    • Its a very strong buy
      0
      • I guess its an even stronger buy today
        0
    • Its merging from the ashes now.
      0
      • Really what happened????
        0
        • $PSTV Plus Therapeutics, Inc. Announces Pricing Of $15 Million Underwritten Public OfferingThe Series U Warrants have an exercise price of $5.00 per share
          0
        • This stupid firm offered millions of share mid-day at 5$ while stock was still trading at 10$. It just took few seconds to drop to 4$. It was unfair of them to do offering at 5$ as lots of bulls got trapped within seconds.
          0
      • After 8 yesterday, first 16, then 3,56 today? What's going on here?
        0
        • 1:50
          0
          • anyone holding the cytori warrants and know how it will be converted - same 50:1 ?
            0
            • This stock has a strong buy technical analysis and it should. Has the potential of quadrupole gains. Bought at 0.33 and looking to make thousands off this when it hits over a 1.00.
              3
              • you missed on this. reverse split in a couple of weeks
                0
              • I don't think so.
                0
            • 8 year was 118 now is 0.4
              1
              • not true..they did two reverse splits
                0
            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.